Chronic kidney disease-mineral and bone disorder: A complex scenario;El complejo escenario de las alteraciones de metabolismo óseo y mineral en la enfermedad renal crónica

Nefrologia

Volumn 31, Issue 5, 2011, Pages 514-519

  Mejia N ^a   Roman Garcia P ^a   Miar, A B ^b   Tavira, B ^a   Cannata Andia J B ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Bone demineralization; CKD MBD; FGF 23; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MINERAL; PARATHYROID HORMONE; PHOSPHORUS;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE; CHRONIC DISEASE; HUMAN; KIDNEY DISEASE; METABOLISM; MORTALITY; PHYSIOLOGY; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

BONE AND BONES; CALCITRIOL; CALCIUM; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MINERALS; PARATHYROID HORMONE; PHOSPHORUS; RENAL OSTEODYSTROPHY; VASCULAR CALCIFICATION;

EID: 82755189181     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Jun.10926     Document Type: Article

References (54)

1. Torregrosa JV, Bover Sanjuán J, Cannata Andía J. Recomendaciones de la Sociedad Española de Nefrologia para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica. Nefrologia 2011;31:3-32.
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
3. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008;35:215-237.
4. Groothoff JW, Lilien MR, Van de Kar NC, Wolff ED, Davin JC. Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 2005;20:374-9.
5. KBS. Calcium and Phosphorus Homeostasis. In: Avner ENP (ed.). Pediatric Nephrology, 5 ed. Philadelphia: Williams & Wilkins; 2005. p. 1347-73.
6. Jüppner HB. Parathyroid Hormone. Philadelphia: Lippincot: Williams & Wilkins; 1999.
7. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14:342-6.
8. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-52.
9. Shimada T, Kakitani M, Yamazaki Y. Targeted ablation of FGF-23 demonstrates an essential physiological role of FGF-23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
10. Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease. Pediatr Nephrol 2006;21:1802-6.
11. Liu S, Tang W, Zhou J. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.
12. Stubbs JR, Liu S, Tang W. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibro-blastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116-24.
13. Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia 2009;29:392-6.
14. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8.
15. Kuro-o M, Matsumura Y, Aizawa H. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
16. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-9.
17. Durán CE, Torregrosa JV, Almadén Y. Dynamics of calcium-regulated PTH secretion in secondary hyperparathyroidism: comparison between "in vivo" vs. "in vitro" responses. Nefrologia 2010;30:73-7.
18. Silver J, Yalcindag C, Sela-Brown A. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int Suppl 1999;73:S2-7.
19. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 2005;S8-12.
20. Brown EM, Pollak M, Seidman CE. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995;333:234-40.
21. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999;277:F157-175.
22. Baker AR, McDonnell DP, Hughes M. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988;85:3294-8.
23. Garfia B, Canadillas S, Canalejo A. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 2002;13:2945-52.
24. Naveh-Many T, Marx R, Keshet E. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990;86:1968-75.
25. Canadillas S, Canalejo A, Santamaría R, Rodríguez ME, Estepa J, Martín-Malo A, et al. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 2005;16:2190-7.
26. Rodríguez M, Canadillas S, López I. Regulation of parathyroid function in chronic renal failure. J Bone Miner Metab 2006;24:164-8.
27. Locatelli F, Cannata-Andia JB, Drueke TB. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-31.
28. Canalejo R, Canalejo A, Martínez-Moreno JM, Rodríguez-Ortiz ME, Estepa JC, Mendoza FJ, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010;21:1125-35.
29. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990;38:931-6.
30. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 2010;25:769-78.
31. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
32. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489-94.
33. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 2005;96:717-22.
34. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-47.
35. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993;91:1800-9.
36. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213-6.
37. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
38. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Luethy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
39. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
40. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003;14:1559-67.
41. Frye MA, Melton LJ, 3rd, Bryant SC, Fitzpa-trick LA, Wahner HW, Schwartz RS, et al. Osteoporosis and calcification of the aorta. Bone Miner 1992;19:185-94.
42. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-53.
43. Naves M, Rodríguez-García M, Díaz-López JB, Gómez C, Rodríguez-Rebollar A, Rodríguez-García M, et al. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008;19:1161-6.
44. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Díaz-López JB, Díaz-Corte C. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009;24:239-46.
45. London GM, Marty C, Marchais SJ. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51.
46. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, et al. 25-hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009;24:611-8.
47. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, De Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008;19:1827-35.
48. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
49. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57.
50. Panizo S, Cardús A, Encinas M. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041-8.
51. Torres PU, Prie D, Molina-Bletry V, Beck L, Silve C, Friedlander G. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007;71:730-7.
52. Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev 2009;8:43-51.
53. Wong YF, Xu Q. Ablation of klotho and premature aging: is 1,25-dihydroxyvitamin D the key middleman? Kidney Int 2009;75:1137-9.
54. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15:437-41.